Boehringer Ingelheim Receives European Marketing Authorization for Jascayd in Pulmonary Fibrosis

MT Newswires · 1d ago
03:25 AM EDT, 07/17/2026 (MT Newswires) -- The European Commission granted marketing authorization for Boehringer Ingelheim's Jascayd treatment for adults with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. The approval follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use in May, according to a Friday release. The positive opinion was based on results from the Fibroneer phase 3 clinical trial program.